Displaying drugs 15151 - 15175 of 15708 in total
Phenacetin
Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).
Withdrawn
1,3,5-trichlorobenzene
Experimental
1-(4-Amidinophenyl)-3-(4-Chlorophenyl)Urea
Experimental
N-(Chlorophenyl)-N'-hydroxyguanidine
Experimental
Posizolid
Posizolid (AZD2563) is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though no results were reported).
Investigational
Matched Iupac: … -2,3-dihydroxypropanoyl]-1,2,3,6-tetrahydropyridin-4-yl}-3,5-difluorophenyl)-5-[(1,2-oxazol-3-yloxy)methyl …
Cannabinor
Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.
Investigational
Indisulam
Investigational
1-[4-(hydroxymethyl)phenyl]guanidine
Experimental
1-(4-thiophen-2-ylphenyl)methanamine
Experimental
4-(2-aminoethyl)-2-ethylphenol
Experimental
(3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE
Experimental
Bromamphenicol
Experimental
(S)-econazole
Experimental
3-(4-NITRO-PHENOXY)-PROPAN-1-OL
Experimental
Displaying drugs 15151 - 15175 of 15708 in total